Rchr
J-GLOBAL ID：201601002325065172
Update date: Mar. 01, 2024
Mouri Atsuto
モウリ アツト | Mouri Atsuto
Affiliation and department：
Job title：
Lecturer
Research theme for competitive and other funds (1)：
- 2017 - 2019 Development of algorithm to enlarge dose interval with Nivolumab for patients with Non-small cell lung carcinoma
Papers (22)：
-
A Case of Eosinophilic Pneumonitis during Immune Checkpoint Inhibitor Treatment after Concurrent Chemoradiotherapy. The Journal of the Japan Society for Respiratory Endoscopy. 2022. 44. 5. 342-347
-
Tsubata Y, Watanabe K, Mouri A, et al. Correction to: Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). International Journal Clinical Oncology. 2022. 27. 823-824
-
Mikiko Nakanishi-Imai, Taro Murai, Masahiro Onishi, Atsuto Mouri, Takafumi Komiyama, Motoko Omura, Shigehiro Kudo, Akihiko Miyamoto, Masaru Hoshino, Shinichi Ogawa, et al. Survey of malignant pleural mesothelioma treatment in Japan: Patterns of practice and clinical outcomes in tomotherapy facilities. Journal of radiation research. 2022. 63. 2. 281-289
-
Tsubata Y, Watanabe K, Mouri A, et al. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). Int J Clin Oncol. 2022 Jan;27(1):112-120. International Journal of Clinical Oncology. 2022. 27. 1. 112-120
-
Mouri A, Kaira K, Kagamu H, et al. Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs. Journal of Clinical Medicine. 2021. 10. 16. 3744
ｍore...
Books (8)：
-
CURRENT THERAPY
2023
-
基礎疾患をどう考慮するか 8 気道狭窄「肺癌薬物療法レジメン Expert's Choice」
メディカルビュー社 2022
-
基礎疾患をどう考慮するか 8 気道狭窄 肺癌薬物療法レジメン Expert's Choice
メディカルビュー社 2022
-
Respiratory Medicine
2021
-
Respiratory Medicine
2021
ｍore...
Lectures and oral presentations (16)：
-
Correlation between T-cell immunity and duration of EGFR-TKI resistance acquisition in patients harboring EGFR activating mutations
(2022)
-
アテゾリズマブの抗腫瘍効果と末梢血T細胞プロファイリング:多施設共同前向き観察研究J-TAIL附随研究
(日本肺癌学会 2022)
-
Correlation with T-cell immunity and EGFR-TKI treatment in patient harboring EGFR driver mutation
(European Society for Medical Oncology(ESMO) 2022)
-
免疫チェックポイント阻害薬によるpseudo progressionと考えられた小細胞肺癌の一例
(呼吸器学会関東地方会 2022)
-
当院におけるオンコマイン遺伝子異常解析の現状と気管支鏡検査における迅速細胞診(ROSE)の有用性の検討
(日本呼吸器内視鏡学会総会 2022)
ｍore...
Professional career (1)：
Association Membership(s) (10)：
日本がん分子標的治療学会
, 日本呼吸器内視鏡学会
, 日本臨床腫瘍学会
, 日本化学療法学会
, 日本肺癌学会
, 日本呼吸器学会
, 日本アレルギー学会
, 日本内科学会
, 日本感染症学会
, 日本環境感染学会
